ANTELOPE DX BV, a Belgium-based diagnostic company focusing on the development of a handheld diagnostic device, today announces that it has received a project grant of 2,5 million euro from VLAIO (Flanders Innovation and Entrepreneurship). The grant will support the development of its point-of-need device and the first diagnostic test. This application is a urine-based self-test which allows the concerned individual to discretely check the presence of the most common sexually transmitted bacterial infections, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) at home.
The Antelope device aims to offer clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag.
“There are very few diagnostic solutions that allow concerned individuals and patients to test their health condition at home. This VLAIO grant validates our approach to take diagnostics in the discrete home setting where both therapy monitoring and acute infectious disease testing will be possible. Being backed by the government to help us execute on this plan is of critical importance,” said Hilde Windels, CEO of Antelope Dx.
About Antelope DX
Antelope DX develops a point of need diagnostic device that allows consumers and healthcare professionals to have on-the-spot access to key health parameters. The Antelope technology aims to offer clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag. The platform is based on an innovative lab-on-chip technology that can perform a sensitive test on any bodily fluid, without requiring complex user operations or sample preparation.
Antelope Dx was founded in July 2019 and has raised EUR 5,1M in its first equity round.